BeyondSpring (BYSI) Competitors $1.82 -0.05 (-2.67%) Closing price 09/12/2025 04:00 PM EasternExtended Trading$1.81 -0.01 (-0.55%) As of 09/12/2025 04:10 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more. Add Compare Share Share Competitors Stock AnalysisChartCompetitorsEarningsFDA EventsHeadlinesOptions ChainOwnershipSEC FilingsShort InterestTrendsBuy This Stock BYSI vs. FHTX, OCGN, SCPH, TVRD, GLUE, DRUG, CAPR, MREO, ACB, and ENGNShould you be buying BeyondSpring stock or one of its competitors? The main competitors of BeyondSpring include Foghorn Therapeutics (FHTX), Ocugen (OCGN), scPharmaceuticals (SCPH), Tvardi Therapeutics (TVRD), Monte Rosa Therapeutics (GLUE), Bright Minds Biosciences (DRUG), Capricor Therapeutics (CAPR), Mereo BioPharma Group (MREO), Aurora Cannabis (ACB), and enGene (ENGN). These companies are all part of the "pharmaceutical products" industry. BeyondSpring vs. Its Competitors Foghorn Therapeutics Ocugen scPharmaceuticals Tvardi Therapeutics Monte Rosa Therapeutics Bright Minds Biosciences Capricor Therapeutics Mereo BioPharma Group Aurora Cannabis enGene Foghorn Therapeutics (NASDAQ:FHTX) and BeyondSpring (NASDAQ:BYSI) are both small-cap medical companies, but which is the better stock? We will contrast the two businesses based on the strength of their dividends, institutional ownership, media sentiment, earnings, analyst recommendations, risk, profitability and valuation. Do insiders & institutionals have more ownership in FHTX or BYSI? 61.6% of Foghorn Therapeutics shares are owned by institutional investors. Comparatively, 40.3% of BeyondSpring shares are owned by institutional investors. 7.6% of Foghorn Therapeutics shares are owned by insiders. Comparatively, 29.3% of BeyondSpring shares are owned by insiders. Strong institutional ownership is an indication that large money managers, hedge funds and endowments believe a stock is poised for long-term growth. Do analysts recommend FHTX or BYSI? Foghorn Therapeutics currently has a consensus target price of $10.67, indicating a potential upside of 105.52%. Given Foghorn Therapeutics' stronger consensus rating and higher possible upside, equities research analysts plainly believe Foghorn Therapeutics is more favorable than BeyondSpring.Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score Foghorn Therapeutics 0 Sell rating(s) 1 Hold rating(s) 3 Buy rating(s) 2 Strong Buy rating(s) 3.17BeyondSpring 0 Sell rating(s) 0 Hold rating(s) 0 Buy rating(s) 0 Strong Buy rating(s) 0.00 Does the media refer more to FHTX or BYSI? In the previous week, Foghorn Therapeutics and Foghorn Therapeutics both had 2 articles in the media. Foghorn Therapeutics' average media sentiment score of 1.76 beat BeyondSpring's score of 0.95 indicating that Foghorn Therapeutics is being referred to more favorably in the media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment Foghorn Therapeutics 1 Very Positive mention(s) 0 Positive mention(s) 0 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Very Positive BeyondSpring 0 Very Positive mention(s) 0 Positive mention(s) 1 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive Is FHTX or BYSI more profitable? BeyondSpring has a net margin of 0.00% compared to Foghorn Therapeutics' net margin of -311.90%. Company Net Margins Return on Equity Return on Assets Foghorn Therapeutics-311.90% N/A -28.00% BeyondSpring N/A N/A N/A Which has preferable valuation & earnings, FHTX or BYSI? BeyondSpring has lower revenue, but higher earnings than Foghorn Therapeutics. CompanyGross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings RatioFoghorn Therapeutics$22.60M12.98-$86.62M-$1.19-4.36BeyondSpring$1.75M41.94-$11.12MN/AN/A Which has more risk & volatility, FHTX or BYSI? Foghorn Therapeutics has a beta of 3.05, meaning that its share price is 205% more volatile than the S&P 500. Comparatively, BeyondSpring has a beta of 0.22, meaning that its share price is 78% less volatile than the S&P 500. SummaryFoghorn Therapeutics beats BeyondSpring on 8 of the 13 factors compared between the two stocks. Get BeyondSpring News Delivered to You Automatically Sign up to receive the latest news and ratings for BYSI and its competitors with MarketBeat's FREE daily newsletter. Subscribe Now View SMS TermsBy entering your phone number and clicking the sign-up button, you agree to receive periodic text messages from MarketBeat at the phone number you submitted, including texts that may be sent using an automatic telephone dialing system. Message and data rates may apply. Message frequency will vary. Messages will consist of stock alerts, news stories, and partner advertisements/offers. Consent is not a condition of the purchase of any goods or services. Text HELP for help/customer support. Unsubscribe at any time by replying "STOP" to any text message that you receive from MarketBeat or by visiting our mailing preferences page. Read our full terms of service and privacy policy. New MarketBeat Followers Over TimeWhat are MarkeBeat Followers?This chart shows the number of new MarketBeat users adding BYSI and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period. Skip ChartMedia Sentiment Over TimeWhat is Media Sentiment?This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.Skip Chart BYSI vs. The Competition Export to ExcelMetricBeyondSpringMED IndustryMedical SectorNASDAQ ExchangeMarket Cap$73.40M$3.15B$5.78B$10.18BDividend YieldN/A2.32%5.73%4.60%P/E RatioN/A21.5775.6326.02Price / Sales41.94254.90462.3591.38Price / CashN/A44.4425.8129.91Price / Book-4.929.6112.766.25Net Income-$11.12M-$53.29M$3.29B$270.76M7 Day Performance-4.21%0.57%0.86%2.54%1 Month Performance-9.90%4.56%4.70%5.73%1 Year Performance-20.87%10.44%69.47%25.85% BeyondSpring Competitors List Export to ExcelCompanyMarketRankShare PriceAnalysts' Price Target1Y Price PerformanceMarket CapRevenueP/E RatioEmployee CountIndicator(s)BYSIBeyondSpringN/A$1.82-2.7%N/A-20.9%$73.40M$1.75M0.0080Gap DownFHTXFoghorn Therapeutics2.7549 of 5 stars$5.43-5.6%$10.67+96.4%-46.6%$306.96M$22.60M-4.56120Positive NewsOCGNOcugen1.8434 of 5 stars$1.03flat$6.00+482.5%-11.6%$301.07M$4.05M-5.1580SCPHscPharmaceuticals4.5133 of 5 stars$5.62+0.7%$7.78+38.5%+2.6%$299.55M$36.33M-3.1030Short Interest ↓TVRDTvardi Therapeutics2.723 of 5 stars$31.82+7.3%$64.25+101.9%N/A$298.47M$7.14M0.0080Positive NewsGLUEMonte Rosa Therapeutics2.5365 of 5 stars$4.83+0.6%$15.33+217.5%-20.9%$298.30M$75.62M13.4290Positive NewsDRUGBright Minds Biosciences3.2816 of 5 stars$42.17-1.9%$81.00+92.1%+3,723.5%$296.88MN/A-45.34N/AHigh Trading VolumeCAPRCapricor Therapeutics2.3541 of 5 stars$6.48+2.0%$22.56+248.1%+38.6%$296.25M$13.39M-3.95101MREOMereo BioPharma Group2.2721 of 5 stars$1.82+1.7%$7.40+306.6%-56.8%$289.38M$10M-26.0040Positive NewsACBAurora Cannabis0.4844 of 5 stars$5.05+4.3%N/A-16.0%$285.07M$246.72M-26.581,130ENGNenGene2.8208 of 5 stars$5.55+2.2%$23.29+319.6%-14.6%$283.61MN/A-3.3631Trending NewsEarnings ReportAnalyst ForecastShort Interest ↑Analyst Revision Related Companies and Tools Related Companies FHTX Competitors OCGN Competitors SCPH Competitors TVRD Competitors GLUE Competitors DRUG Competitors CAPR Competitors MREO Competitors ACB Competitors ENGN Competitors Top 10 Stock Comparisons Semiconductor Stocks Artificial Intelligence Stocks Growth Stocks Magnificent Seven Stocks Pharmaceutical Stocks Ecommerce Stocks Bitcoin Stocks Meme Stocks Cryptocurrency Stocks Cybersecurity Stocks This page (NASDAQ:BYSI) was last updated on 9/15/2025 by MarketBeat.com Staff From Our PartnersOut of 18,347 Cryptocurrencies... This is the ONLY OneThe Single Most Undervalued DeFi Protocol You've Never Heard Of If there's one cryptocurrency you should b...Crypto 101 Media | SponsoredHe Called Nvidia at $1.10. Now, He Says THIS Stock Will…The original Magnificent Seven returned 16,894%—turning $7K into $1.18 million. Now, the man who called Nvi...The Oxford Club | SponsoredWhy Trump’s “Smart Dollar” could rewrite the rulesMUST SEE: Donald Trump's Radical Overhaul of the U.S. Dollar Congress just approved President Trump's lates...Stansberry Research | SponsoredINVESTOR ALERT: Tiny “$3 AI Wonder Stock” on the Verge of Blasting OffRight now, we’re witnessing a monumental shift in the world.Traders Agency | SponsoredForget AI Stocks — This Device Will REPLACE the MicrochipWhile everyone's chasing the same AI plays, George Gilder is focused on something completely different. He ...Banyan Hill Publishing | SponsoredTrump's Law S.1582: $21T Dollar Revolution ComingDo you have money in any of these banks? Chase. Bank of America. Citigroup. Wells Fargo. U.S. Bancorp. I...Brownstone Research | SponsoredRetire Comfortably with These New Monthly Income ETFs?Too many retirees lie awake at night, worried their savings won’t last. Traditional advice and tiny returns ju...Investors Alley | Sponsored“Fed Proof” Your Bank Account with THESE 4 Simple StepsStarting as soon as a few months from now, the United States government will make a sweeping change to bank ac...Weiss Ratings | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added ten stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding BeyondSpring Inc. Please log in to your account or sign up in order to add this asset to your watchlist. Share BeyondSpring With A Colleague Link copied to clipboard. Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
Free BYSI Stock Alerts